CBMT-34. MODULATING DIETARY TRYPTOPHAN OR GUT MICROBIOTA LEVELS DOES NOT IMPROVE THE EFFICACY OF COMBINED TREATMENT WITH RADIATION, ANTI-PD-1 mAb, AND AN IDO1 ENZYME INHIBITOR IN A MODEL OF GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.156
Abstract: Immunotherapy has failed to improve glioblastoma (GBM) patient survival in all phase III clinical trials to-date. We recently discovered that a combination immunotherapeutic approach that simultaneously administers radiation (RT), anti-PD-1 mAb, and an IDO1 enzyme… read more here.
Keywords: ido1; anti mab; gbm; treatment ... See more keywords
A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Gastroenterology"
DOI: 10.1097/mcg.0000000000001356
Abstract: BACKGROUND Network meta-analysis is used as a data synthesizer, incorporating direct and indirect evidence about treatments in a series of randomized control trials. OBJECTIVE To evaluate the comparative efficacy of various treatments for eosinophilic esophagitis… read more here.
Keywords: network meta; treatment; meta analysis; anti mab ... See more keywords
A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine to suppress tumor growth and metastasis in HPV-infected cancers.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e23175
Abstract: e23175Background: PD-1/PD-L1 immunotherapy is viewed as having clinical benefits in advanced cancers but is effective in only a few patients, suggesting that an efficient combination approach is needed to improve efficacy for certain non-small cell… read more here.
Keywords: combination anti; anti mab; mab plus; llo vaccine ... See more keywords
Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6032
Abstract: 6032Background: GLS-010 is a novel fully human anti-PD-1 mAb. Previous Phase I study exhibited favorable result of tolerance, preliminary efficacy and 240mg fixed dose q2w was selected as Recommend... read more here.
Keywords: anti mab; 010 novel; phase; gls 010 ... See more keywords
A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.2577
Abstract: 2577 Background: YH001 is a humanized anti -hCTLA-4 IgG1 mAb that relieves CTLA-4-mediated immunosuppression, and thereby enhances the T-cell-mediated antitumor immune response. Pre-clinical data have shown potent anti-cancer activity when combined with anti-PD-1 mAb. Methods:… read more here.
Keywords: mab; advanced solid; dose escalation; anti mab ... See more keywords
Safety and Immunological Evaluation of Interleukin-21 Plus Anti-α4β7 mAb Combination Therapy in Rhesus Macaques
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.01275
Abstract: Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections compromise gut immunological barriers, inducing high levels of inflammation and a severe depletion of intestinal CD4+ T cells. Expression of α4β7 integrin promotes homing of… read more here.
Keywords: anti mab; plus anti; rhesus macaques; therapy ... See more keywords